Rifampicin resistance in a strain of <i>Brucella melitensis</i> after treatment with doxycycline and rifampicin

Roy, Yves; Grignon, B.; Grollier, G.; Coindreau, M. F.; Becq‐Giraudon, B.

doi:10.1093/jac/18.5.648

Cited by 24 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, resistance patterns have attracted limited interest owing to the acknowledgment of the inability of in vitro observations to predict clinical outcome [37]. Studies on rifampicin resistance in brucellosis may yield useful information regarding the pathogenesis of the disease [38] and may be warranted in tuberculosis-endemic regions where resistance induced by tuberculosis treatment may affect brucella susceptibility [39], yet rifampicin resistance emerging during brucellosis treatment has been randomly reported [40]. The same stands for clinically assessed resistance patterns attributed to sulphamethoxazole/trimethoprim [41] and ciprofloxacin [42], with the resistance pattern of the latter extending to most quinolones.…”

Section: The Role Of Pharmacokinetics Pharmacodynamics and Resistancmentioning

confidence: 99%

New approaches to the antibiotic treatment of brucellosis

Pappas

Solera

Akritidis

et al. 2005

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: The Role Of Pharmacokinetics Pharmacodynamics and Resistancmentioning

confidence: 99%

New approaches to the antibiotic treatment of brucellosis

Pappas

Solera

Akritidis

et al. 2005

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Therefore combinations of the antibiotics: doxycycline, rifampin and streptomycin are applied in order to avoid relapses and to prevent prolonged use of these drugs include [5]. The therapeutic failures have been reported due to antibiotic resistance, which is associated with increasing prevalence of drug-resistance genes for the brucellosis first-line treatment options [6,7]. This situation demands to discover novel drug candidates to combat Brucella’s infection.…”

Section: Introductionmentioning

confidence: 99%

High Throughput Virtual Screening to Identify Novel natural product Inhibitors for MethionyltRNA-Synthetase of Brucella melitensis

et al. 2017

View full text Add to dashboard Cite

The Brucella melitensis methionyl-tRNA-synthetase (MetRSBm) is a promising target for brucellosis drug development. The virtual screening of large libraries of a drug like molecules against a protein target is a common strategy used to identify novel inhibitors. A High throughput virtual screening was performed to identify hits to the potential antibrucellosis drug target, MetRSBm. The best inhibitor identified from the literature survey was 1312, 1415, and 1430. In the virtual screening 56,400 compounds of ChEMBL antimycobacterial library, 1596 approved drugs, 419 Natural product IV library, and 2396 methionine analogous were docked and rescoring, identified top 10 ranked compounds as anti-mycobacterial leads showing G-scores -10.27 to -8.42 (in kcal/mol), approved drugs G-scores -9.08 to -6.60 (in kcal/mol), Natural product IV library G-scores -10.55 to -6.02 (in kcal/mol), methionine analogous Gscores -11.20 to -8.51 (in kcal/mol), and compared with all three known inhibitors (as control) G-scores -3.88 to -3.17 (in kcal/mol). This result indicates these novel compounds have the best binding affinity for MetRSBm. In this study, we extrapolate that the analogous of methionine for find novel drug likeness has been identified [4-(L-histidyl)-2-phenylbenzoyl] methionine hydrochloride, might show the inhibitor of Brucella melitensis effect by interacting with MetRS enzyme. We suggests that Prumycin as a natural product is the novel drugs for brucellosis.

show abstract

“…In vitro susceptibilities of antibiotic susceptibility testing (AST) may change over time and from one geographical region to another (De Rautlin et al, 1986;Kinsara et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

“…Tigecycline (TIG), a member of a new class of antimicrobials, the glycylcyclines, may serve as alternative drug choices (Dizbay et al, 2007;Garcia-Rodriguez et al, 1991;Qadri et al, 1995;De Rautlin et al, 1986).…”

Section: Introductionmentioning

confidence: 99%

In vitro activities of tigecycline against Brucella spp. in an endemic area

Sameera¹

2014

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

Human brucellosis remains a common zoonotic disease worldwide; it has been estimated to cause 500,000 new cases annually. In Saudi Arabia, brucellosis is endemic in different parts of the country due to consumption of unpasteurized milk. In this study, we investigated in vitro activity of tigecycline (TIG) against Brucella spp. isolated at Microbiology Laboratory, King AbdulAziz Medical City over the last 15 years. A total of 704 Brucella species isolates tested against TIG using E-test and MIC were measured. Of the 704 Brucella strain sub cultured, there were 444 isolates (63.07%) with an MIC equal or below 0.125 μg/ml, and the remaining 260 (36.93%) has an MIC between (0.190-2.0 μg/ml). The results of this in vitro study suggest that tigecycline has a promising future to be used as a therapeutic alternative for brucellosis. These observations need to be supported with clinical trials. This is the first study that analyzes a large number of Brucella isolates in our region.

show abstract

Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin

Cited by 24 publications

References 0 publications

New approaches to the antibiotic treatment of brucellosis

New approaches to the antibiotic treatment of brucellosis

High Throughput Virtual Screening to Identify Novel natural product Inhibitors for MethionyltRNA-Synthetase of Brucella melitensis

In vitro activities of tigecycline against Brucella spp. in an endemic area

Contact Info

Product

Resources

About